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Abstract : CDlO is a widely expressed endopeptidase that is present in human colorectal 
cancer (CRC), which shows a high frequency of liver metastasis. CDlO expression in CRC 
cells is associated with liver metastasis in rodent models, and CDlO expression enhances the 
phosphorylation of epidermal growth factor (EGF) receptor (EGFR) and extracellular signal-
regulated kinase (ERK) l/2. Met-enkephalin (MENK), a CDlO substrate, activates its specific 
receptor o -opioid receptor (DOR). which is expressed in CRCs. DOR is a partial agonist of 
ERKl/ 2, which suppresses EGF-induced phosphorylation of EGFR and ERKl / 2. CDlO retains 
EGF-induced EGFR activation by degrading MENK. Paradoxically, CRCs express MENK at a 
high frequency. Since MENK suppresses T lymphocytes, CDlO-expressing CRCs can escape 
from T-cell immunity without exhibiting auto-inhibition. CDlO is strongly associated with the 
metastasis of CRCs to the liver via an immunosuppressive mechanism. Additionally, CDlO may 
be an excellent serum marker for liver metastasis in patients with CRC and could represent a 
potential molecular target for antimetastatic treatment in patients with CRC. 
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CDlO 
Colorectal cancer (CRC) is the fourth leading cause of cancer-related death in Japan, which 
is increasing as the Western lifestyle is becoming more popular in Japanese populations 1l. 
Approximately 24% of CRC invading beyond the submucosal layer shows liver metastasis at 
the time of the original operation and/ or during the follow-up period after operation 2l. One 
third of patients with CRC die from liver metastasis 3l, and only approximately one-third of 
patients with CRC with liver metastasis will respond to systemic chemotherapy; indeed, long-
term survival is rare 3l. Early detection and control of liver metastasis are important factors in 
the treatment of patients with CRC. 
CDlO, also known as common acute lymphoblastic leukemia antigen (CALLA), is widely used 
to define subgroups within B cell-type acute lymphocytic leukemia 4' 5l. CDlO is a 90- to 110-kDa 
cell zinc-dependent membrane metalloendopeptidase, also referred to as neutral endopeptidase 
24.11 (EC 3.4.24.11), enkephalinase, or neprilysin 5l. CDlO is widely expressed in various tissues, 
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including granulocytes, lymphoid germinal centers. lymphoid progenitor cells, placent al 
syncytiotrophoblasts,. renal tubules, glomeruli, mucosal epithelium of the bronchus, stomach, 
intestine, salivary glands, prostate, and gallbladder 6.s). Substrates of the enzyme include a wide 
range of neuropeptides, such as substance P, bradykinin, bombesin. Leu-enkephalin (LENK), and 
Met-enkephalin (MENK) 5' 9' 10). 
CDlO is expressed in CRC and is associated with CRC metastasis, particularly liver metastasis 
2' n: 12). Invasion deeper than the subserosa, venous invasion, lymph-node metastasis, and CDlO 
expression are significantly associated with CRC liver metastases 2). Logistic regression analysis 
showed that lymph node metastasis, CDlO expression, and vascular endothelial growth factor 
(VEGF) expression were significant factors associated with CRC liver metastasis and were 
independent of the incidence of vascular invasion, expression of CD44. and expression of 
transforming growth factor (TGF)- a 12). CDlO expression in cancer stromal cells is associated 
with CRC invasion and metastasis 13). Moreover, CDlO is expressed in the normal mucosa of 
the small intestine but not in the colorectum 14); however, the functions of CDlO in the normal 
intestinal mucosa and CRC are still unknown. 
CDlO enhances liver metastasis 
The role of CDlO expression as a surrogate marker or biological activator of disease 
progression has not yet been defined. In our previous studies, we confirmed that the CDlO-
positive human colon cancer cell line HT29 15) showed inhibition of cell growth, invasion, and 
colony formation following treatment with CDlO antisense S-ODN. In a mouse liver metastasis 
model. HT29 cells treated with CDlO antisense S-ODN showed fewer embedded cells in 
the liver than control HT29 cells. The numbers and sizes of metastatic foci in the livers of 
nude mice were reduced in mice inoculated with CDlO antisense S-ODN-treated HT29 cells 
15). Intraperitoneal administration of liposome-capsulated CDlO antisense S-ODN inhibits the 
establishment of liver metastasis and the growth of established metastases in nude mice 15). 
CDlO substrates 
Substrates of CDlO include a wide range of neuropeptides, such as substance P, bradykinin, 
bombesin, LENK. and MENK 5' 9' 10). Among these neuropeptides, substance P and enkephalin 
participate in mitogen-activated protein kinase (MAPK) signaling 16' 17). Moreover, substance P 
transactivates epidermal growth factor (EGF) receptor (EGFR) 18), whereas enkephalin-induced 
EGFR transactivation is dependent on integrin signaling 19). In G6 glioma cells, which express 
enkephalin receptor ( r3 opioid receptor [DOR]) and EGFR. EGFR activation is inhibited by 
activated DOR. although EGFR does not inhibit DOR 20). Thus, enkephalin degradation by 
CDlO may promote cancer through activation of EGFR. Tumor growth is a balance of cell 
proliferation and apoptosis. CDlO may affect signal diversity during MAPK activation by EGFR 
to increase cell growth and decrease apoptosis. Subsequently, CDlO enhances tumor growth 
and metastasis. 
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CDlO-related intracellular signal pathways 
MAPK activation is known to mediate cell growth. invasion, and survival. Thus, in our 
previous work, we examined the effects of CDlO repression on MAPK phosphorylation 15l. 
CDlO antisense S-ODN treatment increased extracellular signal-regulated kinase (ERK) 1/ 2 
phosphorylation, which is associated with cell growth and invasion 21l. Treatment with CDlO 
antisense S-ODN decreased the phosphorylation of ERKl/2 and EGFR in HT29 cells 15l. In 
contrast, CDlO antisense S-ODN treatment decreased p38 phosphorylation. Moreover, we 
confirmed that p38 inhibition decreased apoptosis in HT29 cells. EGFR is a major activator of 
MAPK in CRCs 22l. Therefore, we examined the effects of CDlO antisense S-ODN treatment 
on EGFR activation. CDlO antisense S-ODN treatment decreased EGFR phosphorylation, 
suggesting that CDlO may be associated with EGFR activation. 
In our recent studies, we demonstrated that DOR is a high-affinity receptor of MENK and 
belongs to the family of the G-protein-related receptors 17). We examined the activation of 
MAPK proteins in HT29 cells and found that the level of ERK phosphorylation in EGFR(+)/ 
DOR(-) cells was higher than that in EGFR(+)/DOR(+) cells. This finding was supported by 
a report suggesting that signals from both EGFR and DOR are transduced via the MAPK 
pathway and that DOR activation modulates EGFR activation and ERKl/2 phosphorylation 
23l. The findings that EGFR knockdown increases the phosphorylation of DOR and that DOR 
knockdown increases the phosphorylation of EGFR suggest that EGFR and DOR interfere 
with the activation of one another. Both DOR and EGFR recruit G-proteins for intracellular 
signaling; hence, their signals may interfere with each other 23l. Additionally, the expression of 
DOR and EGFR in G6 glioma cells has been studied; activation of DOR inhibits the subsequent 
activation of EGFR, whereas activation of EGFR does not inhibit the activation of DOR 20l. 
GRK2, a G-protein, enhances the internalization of DOR but not EGFR 24l. Thus, further studies 
are needed to confirm the relationship between DOR and EGFR. 
Host anticancer immunity and CDlO 
Morphine can decrease the effectiveness of several functions of both natural and adaptive 
immunity and can also significantly reduce cellular immunity 25l. The differentiation function of 
immune cells is significantly affected by opioids 26l. In animal studies, morphine is consistently 
associated with increased morbidity and mortality and promotes cancer progression 25l. Chronic 
administration of opioids decreases the proliferative capacity of macrophage progenitor cells and 
lymphocytes. T-lymphocyte responses are depressed by morphine, as assessed by the inhibition 
of delayed-type hypersensitivity reactions and cytotoxic T-lymphocyte activity, modulation of 
T-lymphocyte antigen expression, and depression of responses to T-lymphocyte mitogens 27l. 
MENK is a neuropeptide that exhibits opium-like effects on the central nervous system. 
Morphine affects the immune system and inhibits cellular immunity 25l. Opioids alter the second 
messenger cyclic AMP, intracellular calcium, and kinases activated by second messengers in 
immune cells 28' 29l. 
Similar to morphine, MENK is an immunomodulator that modifies immune responses 
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to extracellular stimuli, such as mitogens and antigens 301. DOR, the specific receptor of 
MENK, is expressed in T lymphocytes 301• In some contexts, opiates induce apoptosis of T 
lymphocytes through the c-Jun N-terminal kinase (JNK) pathway 311. MENK is produced in high 
concentrations in colon cancer 321, and MENK secretion is associated with tumorigenicity and 
metastasis of CRC cells in syngeneic rodent models 331. MENK concentrations in subcutaneous 
tumors of CT26 and IEC6A rodent CRC cells are inversely correlated with the number of 
tumor-infiltrating T lymphocytes. MENK inhibits the growth of MOL T-4 T-lymphoblastic cells 
in a concentration-dependent manner. Furthermore, MENK increases the phosphorylation 
of ]NK and induces apoptosis in MOL T-4 cells. MENK-induced apoptosis is abrogated by 
treatment with a JNK inhibitor. 
The expression of MENK, DOR, and CD10 was examined in 61 human CRCs by 
immunohistochemistry 341• All tumors expressed MENK. Moreover, DOR and CDlO expression 
was detected in 13 (21 %) and 17 (28%) of the 61 cases. Eleven (73%) of the 15 Dukes' D cases 
with liver metastasis concurrently expressed MENK, DOR, and CD10, whereas two (10%) 
of the 21 Dukes' C cases and none of the Dukes' B cases showed eo-expression of the three 
genes (P < 0.0001). MENK expression is associated with Dukes' staging, nodal metastasis, 
and liver metastasis. MENK concentrations in tumor tissues are higher in Dukes' C cases 
than in Dukes' B cases. Moreover, MENK expression is associated with t umor-infiltrating 
T lymphocytes, particularly those belonging to the CD4+ subset 331• DOR is expressed in 
phytohemagglutinin-stimulated CD4+ and CD8+ T lymphocytes and modulates T lymphocyte 
proliferation, IL-2 production, chemotaxis, and intracellular signaling 351. Exposure to a pure DOR 
antagonist results in dose-dependent suppression of concanavalin A-induced rat T-lymphocyte 
proliferation 361. 
In CRCs, the anticancer immunity of the host is suppressed due to the secretion of several 
cytokines. High-mobility group box 1 (HMGB1) protein induces apoptosis in macrophages 
371, thereby reducing the numbers of tumor-associated macrophages and enhancing t he 
metastasis of CRCs 381• Programmed death-1 (PD-1) is an inhibitory receptor expressed in T 
lymphocytes. The expression of PD-1ligand by CRC cells induces apoptosis in tumor-infiltrating 
T lymphocytes 391• Serum receptor-binding cancer antigen expressed on SiSo cells (RCAS1), 
a membrane molecule expressed on human cancer cells, suppresses tumor-infiltrat ing T 
lymphocytes by inducing apoptotic cell death 40' 411• These factors cause the escape of cancer 
cells from host immunity, thereby enhancing disease progression and metastasis. MENK is 
thought to be one of the primary immune evasion factors in CRCs. 
DOR, a receptor with high affinity for MENK, is a member of the G-protein-related receptor 
family 171. DOR transmits intracellular signals through heterotrimeric G proteins to the family 
of MAPKs 421. In DOR-transfected Jurkat cells, DOR agonists stimulate MAPK phosphorylation 
in a Ras-independent and protein kinase C (PKC)-dependent manner 431• The diversity of DOR 
activity depends on the multifunctionality of MAPK, which is attributed to the activation 
profiles of MAPK family members 441. DOR and K -opioid receptor (KOR) are expressed in T 
lymphocytes with a similar expression pattern to that observed in MOL T-4 cells 45' 461. Notably, 
in MOL T-4 cells, MENK suppresses cell growth in a concentration-dependent manner and 
decreases the phosphorylation of ERK1/ 2 and p38, but increases the phosphorylation of JNK. 
ROLE OF CDlO IN THE METASTASIS OF COLORECT AL CANCER TO THE LIVER (45) 
These results are supported by the findings of a study by Singhal et al. 31l. in which DOR-
induced JNK activation was found to be associated with T-lymphocyte apoptosis. Additionally, 
ERK phosphorylation also attenuated T lymphocyte activation through DOR, which is 
expressed by activated T lymphocytes 47l. 
With the exception of MAPK activation, DOR affects the activation of T lymphocytes in all 
other intracellular events. DOR activation affects intracellular calcium concentrations, and DOR 
agonists increase intracellular free calcium concentrations, whereas MOR is not associated with 
calcium concentrations 48l. In contrast, DOR is negatively coupled with adenylate cyclase for the 
production of cyclic AMP 28l. DOR also plays a role in transcriptional regulation by activating 
activator protein (AP)-1, AP-2, c-fos, Ikaros-1, Ikaros-2, nuclear factor-kappaB, and activating 
transcription factor-2 in immune cells, including T lymphocytes 29' 49l. Ikaros enhances DOR gene 
expression transcriptionally in phytohemagglutinin-activated T lymphocytes 50l. Thus, DOR may 
provide negative feedback for T-lymphocyte activation through several intracellular signaling 
mechanisms. 
CDlO as a serum marker for metastasis of CRC to the liver 
Liver metastasis is a major life-threatening condition in patients with CRC 2l. Early detection 
and treatment are essential for the management of liver metastasis 51). Early detection of liver 
metastasis involves detection of metastasis using imaging or serum markers and prediction 
tools to identify patients who are at high risk of liver metastasis 52). For example, liver 
metastasis has been shown to be highly associated with serum carcinoembryonic antigen levels 
53). Overexpression of sialyl Lewis X, c-erbB2, and c-met is associated with higher malignant 
potential in liver metastasis 54 56l. However, these factors have not been shown to have high 
sensitivity and/ or specificity to predict liver metastasis in patients with CRC. As described 
above, CDlO is an excellent histological marker for liver metastasis of CRC. If CDlO can 
be detected in the serum, this protein may have clinical importance. 
CDlO is expressed at the luminal surface of endothelial cells, the small intestine, and many 
other organs 14' 57l. CDlO is localized mainly on the apical plasma membrane; however, we 
detected CDlO in the stromal space among cancer nests, which suggests that CDlO is secreted 
from CRC cells 34l. Increased levels of CDlO are reported in allergic diseases such as bronchial 
asthma or hemodialysis conditions 58) 59l. These findings suggest that serum CDlO might be a 
possible marker for the liver metastasis in CRCs. 
In a mouse subcutaneous tumor model, serum CDlO is correlated with tumor weights 60l. 
Serum CDlO levels were examined in 84 patients with CRC and were shown to be higher in 
patients with more advanced cancer 60l. Patients with liver metastasis showed the highest levels 
of serum CDlO among all patients. Moreover, patients with high serum CDlO levels were found 
to have had metachronous liver metastasis 60l. 
A cutoff of serum CDlO set to greater than 1000 pg/ mL showed 70% sensitivity and 93% 
specificity for liver metastasis in CRC60l. This cutoff included all cases of metachronous liver 
metastasis. After excluding related conditions, such as allergy or hemodialysis, serum CDlO 
levels may serve as a useful marker of synchronous and metachronous liver metastasis in CRC. 
(46) Kiyomu FUJII et al. 
CDIO targeting 
Since CDlO plays a role in prometastatic mechanisms by affecting host antitumor defense 
through degradation of enkephalin or angiotensin, CDlO is a good candidate for molecular 
targeting therapy. We have previously reported that CDlO knockdown inhibits liver metastasis 
of CRC cells using a mouse model 151. Racecadotril, an antirelaxant drug, and thiorphan and 
AHU377, which are used as antihypertensives, are anti-CDlO drugs 61-631; application of these 
drugs to CRC treatment in large clinical trials may facilitate the identification of effective 
antimetastatic strategies in CRC. 
Conclusion 
MENK exhibits different effects in various cell lineages, including induction of cell survival 
and proliferation in neural cells 641, suppression of T cells 30' 31: 651, and growth inhibition in 
epithelial cells 66' 671• Different responses of MAPK families to MENK may be responsible for 
the diversity of MENK function. In CRC, T-cell suppression is induced by MENK secretion, 
whereas the degrading activity of CDlO on MENK may permit HT29 cell escape from MENK-
induced growth suppression and apoptosis. 
Two clinical applications of CDlO have been proposed. First. CDlO may be an excellent serum 
marker for liver metastasis in patients with CRC. Assessment of serum CDlO levels may enable 
the selection of patients who are at high risk of metachronous liver metastasis of CRC, which 
could facilitate the administrat ion of preventive chemotherapy before the diagnosis of liver 
metastasis. Second. CDlO is a possible target for antiprogressive and antimetastatic treatments 
in CRCs. We observed the antimetastatic effects of the CDlO inhibitor thiorphan with systemic 
administration in mice. Antitumor effects have been reported in the literature 681. Racecadotril, 
which is rapidly metabolized to its active metabolite thiorphan. is already used in clinical 
practice for pediatric diarrhea and is considered safe 611. Concurrent administration of a CDlO 
inhibitor with chemotherapeutic agents should be evaluated to determine its antimetastatic 
effects in colon cancer treatment. 
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